OUR DEVELOPMENT PORTFOLIO
Updated December 2021
-
Oncology -
Cardiometabolism -
Neuroscience -
immuno-inflammation
Phase 1
Haematological malignancies
Mcl1 inhibitor
Haematological malignancies
Bcl2 inhibitor
Haematological malignancies
DHODH inhibitor
Haematological malignancies
UCART19
Solid tumors
Anti CD73
Solid tumors
MAT2A combo
Solid tumors
NKG2A
Solid tumors
PDLx41 BB
Solid tumors
Anti PD1xAnti TIM3 combo
Solid tumors
Anti LAG3
Relapsed or refractory myelodysplastic syndrome (MDS)
Tibsovo®
Grade 2-3 Gliome
Vorasidenib, combo
Phase 2
Non Small Cell Lung Cancer
Anti Met
Sjögren disease
Anti IL7R
Phase 3
Colorectal cancer, 3rd line
Lonsurf® combo
Colorectal cancer, 3rd line
Anti EGFR combo Lonsurf®
Acute myeloid leukemia (AML) IC-eligible, 1st line
Tibsovo® combo
Low-grade Glioma
Vorasidenib